Oncology Institute Inc (TOI) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate TOI’s accelerating shift to risk‑based contracts and scalable pharmacy operations, positioning the firm for profitability and validating its fully delegated care model in a competitive oncology market.

Key Takeaways

• Q2 revenue $119.8M, up 21.5% YoY
• Pharmacy revenue rose 41% YoY, 52% of sales
• SG&A fell to 22% of revenue, 580 bps reduction
• Added 50k capitation lives in Nevada, California
• Full‑year revenue $460‑480M, targeting EBITDA breakeven Q4

Pulse Analysis

The Oncology Institute’s Q2 performance underscores the broader industry transition toward value‑based oncology care. By expanding fully delegated capitation contracts in Nevada, California, and Florida, TOI captures higher per‑member revenue while retaining control over utilization, network design, and claims adjudication. This model aligns incentives across payers and providers, reducing leakage and fostering integrated service delivery—a trend gaining traction as Medicare Advantage enrollment climbs and insurers seek cost‑containment solutions.

Financially, TOI leveraged its growing pharmacy footprint to deliver a 41% year‑over‑year revenue jump, now accounting for more than half of total sales. Scale has improved drug procurement terms and specialty medication rebates, boosting gross margins despite a temporary dip from new capitation contracts. SG&A efficiency improved markedly, falling to 22% of revenue, and the adjusted EBITDA loss narrowed by over 50% YoY. The company’s AI pilots—targeting revenue cycle, prior authorization, and call‑center functions—promise further cost reductions and operational speed, reinforcing the path to profitability.

Looking ahead, TOI’s guidance of $460‑$480 million for full‑year revenue and a projected EBITDA breakeven in Q4 signal confidence in sustained growth. The Florida partnership, which will push Medicare Advantage lives past the 100,000 mark, should generate incremental pharmacy and patient‑service revenue without proportionate SG&A increases. Investors will watch how quickly the newly added capitated populations mature into margin‑positive segments, while the AI initiatives could accelerate that timeline. If execution holds, TOI is poised to emerge as a leading, scalable player in the oncology MSO space, offering a compelling blend of clinical expertise and financial discipline.